title: Re: Bakri et al.: Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials (Ophthalmology 2014;121:1102-8).
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Zygoura
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Kopsachilis
authors.affiliation: Moorfields Eye Hospital, London, UK. Electronic address: gianlucacarifi@gmail.com.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Carifi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology*; D008297:Male; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized